Astra Pill Cuts Hard-to-Treat Blood Pressure in Late-Stage Trial - Bloomberg
Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world Americas+1 212 318 2000 EMEA+44 20 7330 7500 Asia Pacific+65 6212 1000 Listen 3:28 AstraZeneca Plc said its experimental hypertension pill reduced blood pressure by more than twice as much as standard treatment in a large late-stage study, bolstering its chances of competing in a crowded field. The highest dose of the daily baxdrostat pill cut blood pressure by an average 15.7 mm Hg, or millimeters of mercury, when added to other hypertension medicines over 12 weeks, according to the study presented Saturday to the European Society of Cardiology meeting in Madrid. Patients who got a placebo on top of other hypertension drugs saw their blood pressure fall 5.8 mm Hg. Read More: Astra Says Potential Blockbuster Reduced High Blood Pressure Astra had already told investors this year that baxdrostat r
Explore this link on the map →